To explore the multifaceted pathogenesis of Epstein-Barr virus (EBV) and its significant role in modulating immune cell function, as well as to discuss emerging therapeutic strategies targeting EBV-associated diseases.
Key Findings:
EBV is linked to a wide spectrum of diseases, including autoimmune disorders such as multiple sclerosis and systemic lupus erythematosus, as well as malignancies like Burkitt lymphoma and nasopharyngeal carcinoma.
EBV employs multiple immune evasion strategies to maintain latency and modulate host immune responses.
The virus alters host cell biology through various mechanisms, including signaling pathway activation and metabolic reprogramming.
Interpretation:
EBV's ability to modulate immune responses and maintain latency contributes significantly to its pathogenicity in various diseases, necessitating targeted therapeutic approaches that could improve patient outcomes.
Limitations:
The review primarily focuses on the mechanisms of EBV without extensive clinical data, particularly regarding patient outcomes and treatment efficacy.
Future research is needed to elucidate precise molecular pathways and therapeutic targets, especially in the context of clinical applications.
Conclusion:
Understanding EBV's immune modulation and pathogenesis is crucial for developing effective therapies against EBV-associated diseases, highlighting the need for targeted therapeutic strategies.
